A5031121132- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chemokine receptors and signaling
- T-cell and B-cell Immunology
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Treatment and Pharmacology
- Education, Psychology, and Social Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Immune Cell Function and Interaction
- Hematological disorders and diagnostics
- Economic and Fiscal Studies
- Genomic variations and chromosomal abnormalities
- Extracellular vesicles in disease
- Taxation and Legal Issues
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Corporate Taxation and Avoidance
- Immunodeficiency and Autoimmune Disorders
- Melanoma and MAPK Pathways
University Hospital Brno
2016-2025
Masaryk University
2012-2023
Hudson Institute
2017
John Wiley & Sons (United States)
2017
Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired numbers and functions.We analyzed Treg peripheral blood (n = 207) bone marrow 202) pre-malignant malignant MM patients using flow cytometry. their subsets from healthy volunteers were functionally evaluated for suppressive property. A cohort 25 was lymphocytes, CD4 before after treatment cyclophosphamide,...
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating cells (CTCs) until 2021, when this threshold decreased to 5%. We hypothesized that primary PCL not a separate clinical entity, but rather it represents ultra-high-risk multiple myeloma (MM) elevated CTC levels.We assessed levels of CTCs multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM establish cutoff for identifies...
ABSTRACT Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances treatment, some patients progress to more aggressive forms of multiple myeloma, including extramedullary disease or leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed involvement small extracellular vesicle‐enriched microRNAs progression. Therefore, we performed expression profiling these molecules...
Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of EMN02/HO95 MM phase III trial newly diagnosed patients achieving suspected complete before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed bortezomib-lenalidomide-dexamethasone (VRd) no...
Background Multiple myeloma (MM) is a plasma cell malignancy frequently associated with impaired immune numbers and functions. In MM, several studies have previously shown that CD4 regulatory T (Treg) cells hamper effector functions enhance dysfunction. this study, we aimed to prove the presence of functionally suppressive Treg expressing CD8 phenotype (CD8 cells) in MM. To best our knowledge, has not been reported Methods We analyzed their transcription factor FoxP3 from 64 newly diagnosed...
Abstract Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used this purpose; however, approach site‐limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that not site‐limited, but equally challenging. Methods While majority current data comes from short‐term studies, we present long‐term study on...
ABSTRACT Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression‐free survival (PFS) overall (OS). Recently, MRD negativity was approved as an early clinical endpoint accelerated drug approval MM. Nevertheless, there limited evidence utility real‐world setting. In this retrospective multicenter study, we report outcomes 331 newly diagnosed MM patients with evaluation at Day+100 after autologous stem cell...
The purpose of this paper is to run a panel regression analyzing the impact economic, legislative and social factors on corporate tax revenues, as defined by existing empirical theoretical literature. Literature which directly addresses influencing income revenues quite limited - in respect number papers well range examined countries and/or time period. latest key include among others Clausing (2007), Devereux (2006) partly Kenny, Winer Gropp, Kostial (2000). Presented article other hand...
Summary The stem cell marker nestin ( NES ) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, expression diminished but may be re‐expressed following injury or cancer. Surprisingly, we recently confirmed as a tumour‐specific for mature CD 138 + 38 plasma PC multiple myeloma MM ). present study analysed throughout the spectrum developmental stages, starting with individuals no haematological malignancy, through monoclonal gammopathy undetermined...
8011 Background: MRD detection is a sensitive tool to measure response in MM. We assessed by MFC newly diagnosed MM patients (pts) enrolled the EMN02/HO95 phase 3 trial. Methods: Pts were ≤65 years old and received Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction, intensification with Bortezomib-Melphalan-Prednisone (VMP) vs High-Dose-Melphalan (HDM) followed stem cell transplant, consolidation Bortezomib-Lenalidomide-Dexamethasone (VRD) no consolidation, Lenalidomide maintenance....
Multiple myeloma (MM) is a malignancy of plasma cells frequently associated with immune abnormalities. Several studies have confirmed that in MM deregulation can be mediated by increased numbers CD4 T regulatory (Treg) cells, and these were also poor outcome. In this study, we aimed to study CD8 Treg before after lenalidomide plus dexamethasone (len-dex) treatment patients.Using flow cytometry, enumerated assessed suppressive function 16 patients len-dex treatment.Numbers (CD8+CD25hi+FoxP3+)...
Summary Plasma cell leukaemia (PCL) is a rare and very aggressive plasma disorder. Preventing dismal outcome of PCL requires early diagnosis with appropriate analytical tools. Therefore, the investigation 33 patients primary secondary was done when quantity circulating cells (PCs) using flow cytometry (FC) morphology assessment evaluated. The phenotypic profile PCs also analysed to determine if there an association clinical outcomes evaluate prognostic value markers. Our results revealed...
Microparticles (MPs) are small (0.1-1 μm) cell-derived vesicles released during activation or apoptosis, with a surface-exposed phosphatidylserine along antigens indicating the cellular origin. The level of MPs is known to be elevated in thromboembolic diseases and malignancies; it believed that not only amplifying but can also initiate thrombogenesis processes. BCR/ABL negative myeloproliferative neoplasms (MPNs) clonal haematopoietic diseases, which include polycythemia vera,...
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with risk malignant conversion.With the aim to estimate cumulative MGUS progression hematologic malignancies, we analyzed nationwide population-based cohort 1887 patients from Czech Registry Gammopathies (RMG) between 2007 and 2013.During follow-up period (median 4 years; range 0.6-34.8), malignancies was observed in 8.6% (162 1887) patients. Factors associated were as follows: M-protein concentration ≥1.5...
Multiple myeloma (MM) is a malignancy of plasma cells frequently associated with immune abnormalities. Several studies have confirmed that in MM deregulation can be mediated by increased numbers CD4 T regulatory (Treg) cells, and these were also poor outcome. In the present study, we aimed to study CD8 Treg before after lenalidomide plus dexamethasone (len-dex) treatment patients.
Background: Plasmacytoid dendritic cells (pDCs) play prominent roles in mediating innate and adaptive immune responses. However, it is unclear how pDCs contribute to the immunosuppressive tumor microenvironment described multiple myeloma (MM). Methods: Newly diagnosed patients (MM, n = 37) were analyzed determine pDC counts comparison peripheral blood (PB, 53) bone marrow (BM, 10) samples of age-matched healthy donors (HD) using flow cytometry. Second, proliferation presence freshly isolated...
Extramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD a negative prognostic factor of survival. Using flow cytometry next-generation sequencing, we aimed to identify antigens microRNAs (miRNAs) involved pathogenesis. Flow analysis revealed significant differences level clonal between MM patients, while expression CD markers was comparable these two groups. Further,...